



Public Health  
England

Protecting and improving the nation's health

# Hepatitis C in London

## 2015 report

# About Public Health England

Public Health England exists to protect and improve the nation's health and wellbeing, and reduce health inequalities. It does this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. PHE is an operationally autonomous executive agency of the Department of Health.

Public Health England  
Wellington House  
133-155 Waterloo Road  
London SE1 8UG  
Tel: 020 7654 8000  
[www.gov.uk/phe](http://www.gov.uk/phe)  
Twitter: @PHE\_uk  
Facebook: [www.facebook.com/PublicHealthEngland](http://www.facebook.com/PublicHealthEngland)

Prepared by: Paul Crook, PHE Field Epidemiology Services and Emma Burke, Simone Thorn, PHE London.

For queries relating to this document, please contact [fes.seal@phe.gov.uk](mailto:fes.seal@phe.gov.uk)

© Crown copyright 2015

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit [OGL](http://www.ogil.gov.uk) or email [psi@nationalarchives.gsi.gov.uk](mailto:psi@nationalarchives.gsi.gov.uk). Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. Any enquiries regarding this publication should be sent to [Paul.Crook@phe.gov.uk](mailto:Paul.Crook@phe.gov.uk).

Published: November 2015

PHE publications gateway number: 2015410



# Contents

About Public Health England	2
Contents	3
Key findings	4
Summary	4
Recommendations	6
1. Epidemiology and burden of hepatitis C	11
Background	11
New reports of hepatitis C	11
Change in incidence of hepatitis C	12
Risk factors for hepatitis C	13
Burden	18
2. Increasing awareness and reducing undiagnosed infections	25
Trends in testing	26
Site of testing	26
People who inject drugs	28
Testing in prisons	30
3. Prevention and harm reduction	31
People who inject drugs	31
Prisoners	32
4. Treatment of individuals with hepatitis C	33
Estimates of numbers receiving therapy for hepatitis C	34
Care pathways	35
Acknowledgements	37
Data sources	38
Sentinel Surveillance of Hepatitis Testing Study	38
Unlinked Anonymised Monitoring Survey of People Who Inject Drugs	38
About Field Epidemiology Services	39
Appendix 1	40
Appendix 2	42
References	45

## Key findings

In response to the Hepatitis C Action Plan for England, published in 2004, public health action is focused on four main areas:

- prevention of new infections
- increasing awareness of infection
- increasing testing and diagnosis
- getting diagnosed individuals into treatment and care

This report focuses on the epidemiology of hepatitis C in London, using the main routinely available surveillance data, and provides recommendations for stakeholders on measures to prevent further infections and to reduce the morbidity and mortality of those already infected.

### Summary

Hepatitis C is a blood borne virus. Infection is usually asymptomatic in the early years. The majority of infected individuals are unable to clear hepatitis C naturally, and without successful treatment, chronic infection can span several decades and can be lifelong. Persistent infection can lead to end stage liver disease (ESLD) and hepatocellular carcinoma (HCC).

An estimated 60,000 people in London have been infected with hepatitis C (ie they are hepatitis C antibody positive), of whom an estimated 40% remain undiagnosed.

Compared to other areas, London has a high rate of laboratory confirmed hepatitis C diagnoses. There were 3,858 new laboratory reports of confirmed hepatitis C diagnosis in London in 2014, a rise of 25% since 2013. This rise may reflect improvements in reporting (laboratory reporting became a statutory requirement in 2010) as opposed to an increase in underlying detection of infections. The number of newly acquired infections (as opposed to new reports) of hepatitis C per year appears to be stable or declining.

In 2014, over 2,000 people in London were admitted to hospital with a diagnosis of hepatitis C. Hepatitis C was the primary indication for just under a quarter of first liver transplants in London.

Injecting drug use remains the major risk factor. It is estimated that over half of people who inject drugs (PWID) in London have hepatitis C (60%). In the past 10 years, sex between men has also emerged as an important route of transmission. Individuals

originating from south Asia, where the prevalence of hepatitis C is high, are also particularly at risk. The number of diagnoses overall is highest in males, the peak age group being 35 to 54 years.

If left untackled, hepatitis C infection will result in great costs, not only in terms of morbidity and mortality due to chronic disease, but also in financial costs due to treatment of the late complications of the infection. Hospital admissions from hepatitis C related ESLD and HCC in the UK have nearly tripled in the past decade (2004–2013) and deaths more than doubled.

Raising awareness, leading to increased testing, is important to identify previously unrecognised cases. However, for those with continued risk factors, repeat testing is also important. It is encouraging to see evidence that testing for hepatitis C has increased in recent years, especially in primary care. Furthermore, testing of clients in drug addiction treatment services continues to steadily rise, to 80% in 2013/14, although there is marked variation by local authority across London. Reported testing in prisons is poor, with 6.4% of new receptions in London reported as having been tested, compared with 7.8% in England.

Prevention is primarily focused on PWID and there has been marked success in reducing the sharing of drug paraphernalia through needle exchange schemes. However, more needs to be done to ensure that service users can access the right equipment and hear the right harm reduction messages. There is evidence that a significant proportion of PWID continue to share injecting equipment (32% indirect and direct sharing).

It is vital that those testing positive and shown to be chronically infected are referred appropriately. Only a quarter of London prisons and a minority of providers of services for PWID reported having written care pathways in place.

Treatment can be effective at clearing the virus and a new generation of anti-hepatitis C treatments is likely to revolutionise the outlook for infected patients. NHS England is responsible for commissioning and funding access to the newer drugs, which will be available for patients with cirrhosis who are in the most need, via four operational delivery networks in London.

## Recommendations

**GPs** are advised to:

- ensure that those people at increased risk of infection are identified and tested, and the chronically infected are referred to a specialist for follow-up (even if the risk was many years ago)
- explore ways to improve their knowledge of hepatitis C, including undertaking e-learning or other training such as the Royal College of General Practitioners (RCGP) certificates in the Detection, Diagnosis and Treatment of Hepatitis C (and B) in Primary care, and Hepatitis C: Enhancing Prevention, Testing and Care
- ensure appropriate harm reduction messages are given to patients to help them manage the condition and reduce health harms

**Directors of Public Health** are advised to consider:

- raising the profile of hepatitis C in their area, highlighting the costs associated with the sequelae, the benefits of early diagnosis and treatment, and the need for quality prevention services for PWID
- encouraging co-ordinated work to raise awareness among the general population and those at increased risk of hepatitis C
- liaising with the clinical commissioning group (CCG) to ensure that there are robust local care pathways in place—from primary care and drug treatment services to hepatology services
- ensuring that there is an on-going education programme for professionals providing health and social care services for people at increased risk of hepatitis C, utilising free resources such as those available from the RCGP
- ensuring the inclusion of hepatitis C in the health and wellbeing board's joint strategic needs assessment
- reviewing current local provision against the 2014 NICE Public Health Guidelines 52 for needle and syringe programmes
- ensuring continued investment in testing for hepatitis C in local drug and alcohol services, and in needle and syringe programmes, via the public health grant

**Local authorities and commissioners of drug treatment services** are advised to consider:

- ensuring that a broad range of prevention services (including harm reduction advice, needle exchange and opioid substitution treatment) is available for PWID, including those among men who have sex with men (MSM) and those who inject new psychoactive substances or image and performance-enhancing drugs
- ensuring a high rate of hepatitis C testing in those attending specialist services for drug users, including monitoring repeat testing for PWID who have continued risk factors
- providing harm reduction advice to reduce the spread of infection in PWID, including advice regarding lifestyle factors for those who test positive, such as reducing alcohol intake
- ensuring that specialist services for drug users collect robust information on hepatitis C testing and consider how they may capture the more detailed blood-borne virus data items that the National Drug Treatment Monitoring System (NDTMS) can record
- working closely with clinical commissioning groups (CCGs) to ensure that CCG and local authority (LA) commissioning is aligned, and with local hospitals to ensure that clear pathways are developed from testing into treatment services
- ensuring that sexual health services are offering hepatitis C testing to those at increased risk, for example MSM
- ensuring that homeless services are offering hepatitis C testing to those at increased risk

**Clinical commissioning groups** are advised to:

- ensure that integrated and robust pathways of care are available for patients with hepatitis C, ideally co-ordinated through a clinical network. This includes pathways for patients who test positive for hepatitis C in primary care
- consider delivery of hepatitis treatment to PWID in a community drug treatment setting
- commission to ensure that acute providers provide robust information on the numbers of patients with hepatitis C who are referred, seen and treated for hepatitis C and their clinical outcomes

**NHS England** is advised to:

- take measures to increase testing in primary care, especially in those areas with large populations at increased risk
- continue the roll out of the new operational delivery networks for the provision of the new drugs and support the development of pathways to access treatment from drug treatment services
- provide clear advice to all parties about access to and eligibility for the new drugs
- collect data on the number of people referred to hepatology for hepatitis C treatment, the number that start treatment, and the outcome achieved for these patients
- improve the uptake of hepatitis C testing in prisons
- ensure that Prison Health Services have testing strategies and written care pathways that allow equitable access to treatment services for offenders
- ensure that there is an ongoing education programme for professionals providing services for people at increased risk of hepatitis C infection

**Providers of prison health services** are advised to:

- develop testing strategies and written care pathways that allow equitable access to treatment services for offenders. These should be designed to meet the challenges of both the prison environment and continuity of care in the community. All prison health services should increase reported testing of hepatitis C
- further expand the use of newer technologies, like dried blood spot testing, that make testing easier in non-clinical settings
- provide in-house treatment of hepatitis C

**Providers of drug treatment services** are advised to:

- ensure all PWID entering services are tested for hepatitis C and are supported to take up the test, and that those with continued risk factors are offered regular repeat testing
- ensure all relevant staff have appropriate training on hepatitis C detection, diagnosis and management, utilising free resources such as those available via the RCGP



- raise awareness of local pathways to hepatology services and refer those who test positive
- ensure that service users are offered continued harm reduction advice to reduce the spread of infection, including those who have already tested positive, as well as those who are currently negative, but report continued risk factors
- make use of the free resources available via the Harm Reduction Works website to raise awareness among PWID: [http://www.harmreductionworks.org.uk/hep\\_c.html](http://www.harmreductionworks.org.uk/hep_c.html)
- further expand the use of newer technologies, like dried blood spot testing, that make testing easier in non-clinical settings

**Providers of hepatitis C treatment services** are advised to consider:

- providing robust information on the numbers of patients with hepatitis C who are referred, seen and treated for hepatitis C and their clinical outcomes
- providing delivery of hepatitis treatment to PWID in a community drug treatment setting

**PHE London** is advised to:

- work with commissioners and providers to encourage increased testing rates of those at increased risk, especially those in drug treatment, including repeat testing for those with continued risk factors (ie those currently injecting)
- support and encourage the development of robust pathways from place of testing, especially drug treatment services, into hepatitis treatment services, where these are not in place

**Laboratories** are advised to consider:

- automatically testing samples that are positive for hepatitis C antibody for the presence of hepatitis C virus (for example, using a polymerase chain reaction assay), or refer the sample to a laboratory that can perform this test
- ensuring that Public Health England health protection teams are notified of cases of hepatitis C infection, in line with national public health legislation

**People who inject drugs (PWID)** are advised to:

- use a full set of clean equipment for each injecting episode
- request testing if they have not been offered it
- request referral to hepatology services if they test positive
- make use of resources on the Harm Reduction Works website to keep themselves safe and reduce health harms: [http://www.harmreductionworks.org.uk/hep\\_c.html](http://www.harmreductionworks.org.uk/hep_c.html)
- make use of resources available from the Hepatitis C Trust for those who test positive

# 1. Epidemiology and burden of hepatitis C

## Background

Hepatitis C remains a major public health problem, with an estimated 214,000 adults living with chronic infection in the UK.<sup>1</sup> The Public Health England (PHE) *Hepatitis C in the UK, 2015 report* provides a comprehensive review of the epidemiology of hepatitis C nationally.<sup>2</sup>

Hepatitis is a general term meaning 'inflammation of the liver'. Hepatitis C is caused by infection with the hepatitis C virus (HCV). Symptoms can include anorexia, abdominal discomfort, nausea and vomiting, fever and fatigue, progressing to jaundice in approximately a quarter of patients. However, it can often be asymptomatic. Of those exposed to hepatitis C, about 40% recover; but the remainder, whether they have symptoms or not, become chronic carriers, and may develop cirrhosis, with up to 20% developing hepatocellular carcinoma (HCC).<sup>3</sup>


Information from various sources can be used to build up a picture of hepatitis C epidemiology in London. We do not have complete information about hepatitis C because we are not able to accurately determine the number of new infections each year and there is no prevalence survey of the local general population.

## New reports of hepatitis C

New laboratory reports do not provide a good guide to new infections, as hepatitis C is usually asymptomatic and there is no laboratory marker of recent infection. Therefore, changes in the numbers diagnosed in laboratories often reflect trends in testing or reporting, rather than incidence.

The number of laboratory confirmed diagnoses of hepatitis C from laboratories has continued to rise steadily since 2010. There were 3,858 diagnoses confirmed in London in 2014, a rise of 25% compared to 3,079 in 2013 (Figure 1). Recent rises are likely be due to increased reporting as opposed to an increase in infection detection since laboratory reporting became a statutory requirement in 2010.<sup>4</sup>

**Figure 1: Laboratory confirmed diagnoses of hepatitis C from laboratories in London, 2005–14<sup>5</sup>** (increases are likely to reflect improved testing and reporting)



London alone accounts for a third (34%) of all hepatitis C diagnoses reported in England in 2014<sup>2</sup> and has the highest rate of laboratory confirmed diagnoses when compared to other PHE Centre areas (Figure 2). However, caution should be applied when comparing London to other Centres as you are not specifically comparing London with other large cities. The number and rate of laboratory reports in 2014 by local authority is presented in Appendix 1.

**Figure 2: Rate of laboratory confirmed diagnoses of hepatitis C per 100,000 residents, by PHE Centre, 2014<sup>5</sup>**




### Change in incidence of hepatitis C

As most new infections are acquired via injecting drug use, which often begins in late adolescence and early adulthood, the number of positive tests in individuals aged 15 to 24 years has been used as a proxy indicator of incidence.

Using this proxy, the incidence of hepatitis C appears to be stable or declining. Although the number of 15- to 24-year-olds tested for hepatitis C has increased over recent years, the proportion testing positive is stable in 15 to 19-year-olds and the proportion testing positive has declined in the 20 to 24 year age group (Figure 3).

**Figure 3: Number of young adults tested and testing positive for anti-HCV in sentinel laboratories in London, 2010–14<sup>6</sup>**



In England, Wales and Northern Ireland, recent transmission of hepatitis C has been explored among the participants in the PHE’s Unlinked Anonymous Monitoring Survey of PWID<sup>7</sup> by looking for those who have recently developed antibodies to hepatitis C. Across the UK, a number of methods have been used to gain insight into the number of new HCV infections and likely trends in incidence over time. Preliminary data suggests that incidence of hepatitis C infection among PWID in England, Wales and Northern Ireland during 2014 was between 5 and 16 infections per 100 person years of exposure.<sup>2</sup>

### Risk factors for hepatitis C

A number of groups are at increased risk of hepatitis C (Table 1). The principal risk factor is injecting drug use. Robust London data is unavailable but national data highlights that people who inject drugs (PWID) account for nine out of every 10 diagnoses of hepatitis C in England (Table 2).<sup>2</sup> However, for the vast majority of people this information is not available and therefore this figure may not be representative of all those testing positive.

**Table 1: Risk groups for hepatitis C<sup>8</sup>**

People who have ever injected drugs

People who received a blood transfusion before 1991 or blood products before 1986, when screening of blood donors for hepatitis C infection and heat treatment for inactivation of viruses were introduced

People born or brought up in a country with an intermediate or high prevalence (2% or greater) of chronic hepatitis C. Although data is not available for all countries, for practical purposes this includes all countries in Africa, Asia, the Caribbean, Central and South America, Eastern and Southern Europe, the Middle East and the Pacific islands

Babies born to mothers infected with hepatitis C

Prisoners, including young offenders

Looked-after children and young people, including those living in care homes

People living in hostels for the homeless or sleeping on the streets

HIV-positive men who have sex with men

Close contacts of someone known to be chronically infected with hepatitis C

**Table 2: Risk factor information in laboratory reports of hepatitis C infection from England, 1996–2014<sup>4</sup>**

Risk factor (where reported)	Number of reports	Percentage (%)
PWID	16,883	90.6
Transfusion	240	1.3
Blood product recipient	132	0.7
Sexual exposure	188	1.0
Renal failure	74	0.4
Vertical (mother to baby) or household	42	0.2
Occupational	17	0.1
Other	1,060	5.7
Total	18,198	100

## People who inject drugs (PWID)

The prevalence of hepatitis C among PWID is known to be high. The PHE's Unlinked Anonymised Monitoring Survey of PWID (more information in data sources) measures changing prevalence of hepatitis C in current and former PWID.<sup>7</sup> In London, this survey estimated the prevalence of hepatitis C in PWID to be 60% in 2014, which is similar to levels recorded in 2005.

## Prisoners

A relatively high proportion of prisoners have hepatitis C, most likely due to injecting drug use. Of the prisons that were included in sentinel surveillance, 9% of those tested from 2010 to 2014 were antibody positive.<sup>6</sup>

## Men who have sex with men

Men who have sex with men (MSM) are a risk group for hepatitis C transmission. Enhanced Surveillance of Newly Acquired Hepatitis C infection in MSM collected data prospectively from 22 centres in London, Manchester and the south east. Between January 2008 and December 2014, 470 recently acquired cases of hepatitis C were reported, the majority (94%) of whom were HIV positive.<sup>9</sup>

Among HIV positive men, the estimated incidence of hepatitis C declined over time from 7.3 per 1,000 person years in 2008 to 2.3 in 2013.

Almost a half of men with hepatitis C reported a recent history of unprotected insertive (47%) and receptive (52%) anal intercourse, non-injecting recreational drug use (54%) and sex under the influence of drugs (47%). A recent STI diagnosis was reported among 44% of men alongside high rates of partner change in the previous three months. In addition, a third (27%) of men reported a history of injecting drug use.

These findings provide evidence of ongoing, but declining, sexual transmission of hepatitis C among HIV-positive MSM, which may have been driven by an increase in awareness as a result of timely hepatitis C campaigns. Therefore, accurate and appropriately tailored information on the risk factors for hepatitis C transmission must continue to be made available. Furthermore, these findings underscore the British HIV Association (BHIVA) guidelines that recommend that all patients with HIV should be screened for hepatitis C at the time of their diagnosis—annually among known positive patients, more frequently for those at higher risk of infection, and among all those with abnormal liver function tests.


## Ethnicity

Eight laboratories in London participate in the Sentinel Surveillance of Hepatitis Testing Study, which means they collect more detailed information about hepatitis C testing (more information in data sources).<sup>6</sup>

This data suggests that the proportion of those tested that are positive for hepatitis C varies by ethnicity. Overall in London, White ethnic groups were more likely to test positive (1.9%) than Asians (1.5%) and Black ethnic groups (0.7%) in 2014. This is likely to reflect different levels of injecting drugs in these groups.<sup>6</sup>

The prevalence of hepatitis C in individuals originating from South Asia is higher than that in the general non-injecting population<sup>1</sup>. The proportion of those testing positive has declined over the last five years, partially as a result of increased testing reducing the pool of undiagnosed infection (Figure 4).

**Figure 4: Number of South Asian individuals tested and testing positive for anti-HCV in sentinel laboratories in London, 2010–14<sup>6</sup>.** NamPehchan software was used to identify individuals of South Asian origin because ethnicity is not routinely available from the participating laboratory information systems.




Eastern Europeans may be at increased risk of hepatitis C. Over the period 2010–2014 in England, 5% of people of Eastern European origin tested positive.<sup>2, 6</sup>

## Age and sex

Figure 5 shows that males account for 72% of those testing positive for hepatitis C, with the peak age group being those aged 35–54 years.




**Figure 5: Age-group and gender of individuals testing positive for anti-HCV in sentinel laboratories in London, 2014<sup>6</sup>**



**Other risk factors**

We have limited information on what proportion of individuals who are tested for hepatitis C are positive according to the reason why they were tested as, for 95% of cases, this information is missing (Figure 6). Where a reason was given, nearly a fifth of those tested because they were PWID were positive. Other relatively high positivity rates were found in those tested due to contact testing (8.8%), because they travelled or lived abroad (6.5%), or due to sexual exposure (5.7%).

**Figure 6: Percentage of individuals testing positive for anti-HCV by risk/reason for test in sentinel laboratories in London, 2010–14<sup>6</sup> (LFT-liver function test)**



## Burden


### Estimates of the number of people infected with hepatitis C

It is estimated that over 60,000 people have been infected with hepatitis C in London ie they are hepatitis C antibody positive (Appendix 2). Of these, an estimated 41,500 (69%) are RNA positive (ie they have not cleared their infection). The estimated number of individuals who have been infected with hepatitis C varies considerably across London local authorities (LAs), with the highest number in the Lambeth Drug Action Team (DAT) area (~3,605). Variations reflect differences in underlying populations, for example in drug use, ethnicity and prison populations. Please note some of the limitations with this modelling approach, outlined on page 43.

It should be noted that a large proportion of people who have been infected with hepatitis C in London are those who used to inject drugs many years ago and no longer inject (40%).

It is estimated that a smaller proportion of people in London who have been infected with hepatitis C have never injected drugs (20%), just under one half of whom are Indian, Pakistani or Bangladeshi (9% of total). The corresponding figures for each LA are displayed in Figure 7.

**Figure 7: Estimates of the proportion of all people who have been infected with hepatitis C in each London LA in each risk group<sup>10</sup>**



## Modelling the burden

In order to plan services effectively, it is important to estimate the number of people likely to need treatment. To support commissioners, PHE has developed a model that estimates the prevalence of hepatitis C infection by drug action team (DAT) area, the burden of disease and treatment needs. This model can be found in Appendix 2.<sup>5, 10, 11</sup>

The model uses estimates of the proportion of those already infected with hepatitis C who have already been diagnosed (~60%). Of these, a certain proportion are assumed to have already been successfully treated, based on regional sales/dispensing data and reported sustained virological response (SVR) rates. The number of those people already infected who are newly diagnosed each year with 'steady state' testing activity is also calculated.

## Hospital admissions for hepatitis C


Hospital admissions from hepatitis C related ESLD and HCC in the UK have nearly tripled in the past decade (2004–2013) and deaths more than doubled.

The number of admissions due to hepatitis C in London remains high. Although it is likely that hospital episode statistics underestimate the true numbers of admissions from hepatitis C, in 2014, 2,072 London residents were admitted to hospital with hepatitis C (Figure 8) which is similar to the number admitted in 2008.<sup>12</sup>


Since 2008 increases have been seen in the number of people admitted due to hepatitis C related ESLD (355 in 2014, 28% increase since 2008) and HCC (151 in 2014, 51% increase since 2008) (Figures 9 & 10).<sup>12</sup>

**Figure 8: Individuals resident in London admitted to hospital with a diagnosis of hepatitis C, 2008–14<sup>12</sup> \*, \*\*\* see footnotes on next**


page for figures 9&10



**Figure 9: Individuals resident in London admitted to hospital with a diagnosis of HCV related ESLD, 2008–14<sup>12</sup> \*, \*\*, \*\*\***



**Figure 10: Individuals resident in London admitted to hospital with a diagnosis of HCV related HCC, 2008–14<sup>12</sup> \*, \*\***



Data source: Health and Social Care Information Centre, Hospital Episode Statistics; Copyright © 2015, re-used with the permission of the Health and Social Care Information Centre, all rights reserved

Data relate to the number of individuals who were admitted to hospital and the episode in hospital ended in each calendar year. If an individual had more than one episode in the calendar year - we have only counted them once for this particular analysis ie all patients with HCV/ESLD/HCC admissions were de-duplicated to give one individual with HCV/ESLD/HCC per calendar year.

Codes for HCV/ESLD/HCC were extracted from all diagnosis codes (information about a patient's illness or condition - this includes primary/secondary/subsidiary diagnoses) - The following ICD10 codes were used: B171 (Acute hepatitis C), B182 (Chronic viral hepatitis C), C220 (Liver cell carcinoma), and the following codes for ESLD (our definition of ESLD is defined by codes or text entries for ascites (R18), bleeding oesophageal varices (I850), hepato-renal syndrome (K767), hepatic encephalopathy or hepatic failure (K704) (K720) (K721) (K729).


\*Patient counts are based on the unique patient identifier, HESID. This identifier is derived from a patient's date of birth, postcode, sex, local patient identifier and NHS number, using a standard algorithm. Where data are incomplete, HESID might wrongly link episodes or fail to recognise episodes for the same patient. Care is therefore needed, especially where the data includes duplicate records. Patient counts must not be summed across a table where patients may have episodes in more than one cell.

\*\* Defined by codes for ascites, bleeding oesophageal varices; hepato-renal syndrome, hepatic encephalopathy or hepatic failure.

\*\*\* Hospital Episode Statistics (HES) data for 2013 and 2014 were analysed using the HES Data Interrogation System (HDIS). HDIS is a remotely accessed secure data portal provided and hosted by the Health and Social Care Information Centre (HSCIC) for the purposes of analysing HES data in a secure environment.

The crude hospital admission rate for hepatitis C related ESLD or HCC in London (5.5 per 100,000) is significantly higher than the rate in England (3.5 per 100,000, 2012/3).<sup>13</sup> There is four-fold variation across local authorities, from 13.3 per 100,000 in Camden to 3.3 per 100,000 in Havering (Figure 11).<sup>13</sup> Ten local authorities have rates significantly above the England rate: Camden, Hammersmith and Fulham, Westminster, Lewisham, Hackney, Islington, Enfield, Waltham Forest, Brent and Wandsworth.

**Figure 11: Crude hospital admission rate for hepatitis C related end-stage liver disease and hepatocellular carcinoma, persons per 100,000 population by London local authority, 2012/3.** <sup>13</sup> (City of London not displayed due to wide confidence intervals, Bexley, Harrow, Kingston upon Thames, Richmond upon Thames values suppressed for disclosure control due to small count)




### Transplants


The number of first registrations in Londoners for liver transplants with post-hepatitis C cirrhosis as a primary, secondary or tertiary indication observed during 2010–14 (n=143) was higher than levels reported in the previous five-year periods (Figure 12).<sup>14</sup>

A similar but less marked trend was seen for the number of first liver transplants with post-hepatitis C cirrhosis as a primary, secondary, or tertiary indication (Figure 13). These indications accounted for 22% of all liver transplants in Londoners during 2010–2014.

**Figure 12\*: First registrations with post-hepatitis C cirrhosis as primary, secondary or tertiary indication for transplant, London residents, 2000–2014<sup>14</sup>**



**Figure 13\*: First liver transplants with post-hepatitis C cirrhosis as primary, secondary or tertiary indication for transplant at registration who were hepatitis C positive at registration or transplant, London residents, plus percentage of all liver transplants, 2000–2014<sup>14</sup>**




\* These figures are based on registry data as at 09 April 2015. New national registration criteria for selecting adult patients for elective liver transplantation were introduced in September 2007: NHSTB. Liver Transplantation: Selection Criteria and Recipient Registration (June 2015). Available at: <http://www.odt.nhs.uk/transplantation/guidance-policies/> (Accessed 19/06/2015).

## Deaths from hepatitis C

London and the North West PHE Centres have the highest rates of death in England from ESLD or HCC in individuals with hepatitis C mentioned on their death certificate (Figure 14).<sup>15</sup>


**Figure 14: Map showing the rate of death from end-stage liver disease (ESLD) or hepatocellular carcinoma (HCC) in individuals with hepatitis C mentioned on their death certificate by PHE Centre, 2008–14<sup>15</sup>**



The under 75 crude mortality rate from hepatitis C related ESLD or HCC varies 10-fold across London, from 1.67 per 100,000 in Lambeth to 0.15 per 100,000 in Bexley from

2011–13 (Figure 15).<sup>13</sup> However, only Lambeth, Hammersmith and Fulham, Westminster and Barnet local authorities have rates significantly above the England rate.<sup>13</sup>

**Figure 15: Crude mortality rate from hepatitis C related end-stage liver disease/hepatocellular carcinoma in persons less than 75 years per 100,000 population by London local authority, 2011–13<sup>13</sup>** (City of London is not included due to very wide confidence intervals)





## 2. Increasing awareness and reducing undiagnosed infections

Hepatitis C is usually asymptomatic in the early years, therefore many individuals remain undiagnosed. The *Hepatitis C Action Plan for England*<sup>16</sup> identified that raising awareness among both the public and professionals was an important component of reducing the burden of undiagnosed infection. With many new and improved treatments becoming available, it is increasingly important to raise awareness of the infection so that more individuals can be diagnosed and treated.

Awareness campaigns in England are now well established. In 2009, the Department of Health launched campaigns targeting former PWID (Get Tested, Get Treated)<sup>17</sup> and the UK population of South Asian origin (Hepatitis C. The more you know, the better).<sup>18</sup>

The Royal College of General Practitioners (RCGP), HCV Action and The Hepatitis C Trust, have launched an educational film to support primary care in increasing their knowledge about hepatitis C and help them build confidence in diagnosing and supporting people through treatment (<http://hcvaction.org.uk/resource/film-detecting-managing-hepatitis-c-primary-care>).

The RCGP Certificate in the Detection, Diagnosis and Management of Hepatitis B and C in Primary Care was developed to help raise awareness in primary care and among other professionals working with groups at high risk of chronic viral hepatitis infection. In London, 238 individuals had completed the e-learning module and 97 had attended face-to-face training days by December 2014.<sup>2</sup> To supplement this, a new RCGP course was launched in April this year, '*Hepatitis C: Enhancing Prevention, Testing and Care*' which comprises four lessons: understanding hepatitis C; preventing transmission; testing and diagnosis; and treatment and care.

The National Institute for Health and Care Excellence (NICE) published its public health guidance *Hepatitis B and C: ways to promote and offer testing to people at increased risk of infection* in 2012.<sup>8</sup> This included a summary of available evidence and recommendations to a range of stakeholder organisations, which covered the following areas:

- awareness raising among the general population and people at increased risk of hepatitis C
- developing the knowledge and skills of healthcare professionals and others providing services for people at increased risk of hepatitis C


- testing in primary care, prisons, immigration removal centres, drugs services and sexual health services.
- commissioning of hepatitis C testing and treatment services
- laboratory services for hepatitis C testing

### Trends in testing

Trends in testing are one indicator of increased awareness and, encouragingly, there has been an increase in testing in London since 2010.<sup>6</sup> The data in Figure 16 from sentinel surveillance shows the numbers tested and proportions positive in London.<sup>6</sup>

The proportion testing positive for hepatitis has decreased year-on-year from 2.6% in 2009 to 1.7% in 2014. This decline in positivity may be the result of extending testing to individuals at relatively lower risk of infection or the beneficial effect that an increase in testing has had on decreasing the proportion of the long-term infected who remain undiagnosed.


**Figure 16: Number of individuals tested and the proportion testing positive for anti-HCV in sentinel laboratories in London, 2010–14.**<sup>6</sup> Please note that the numbers relate to those tested in the sentinel laboratories, and do not represent all tests across London



### Site of testing


Information from sentinel surveillance indicates that testing was most often conducted by general practitioners (Figure 17).<sup>6</sup> However, this data does not include dried blood spot testing or oral fluid testing (commonly used in drug services).

**Figure 17: Number of individuals tested for anti-HCV and the proportion testing positive by service type in sentinel laboratories in London, 2010–14.**<sup>6</sup> Please note that the numbers relate to those tested in the sentinel laboratories and do not represent all tests across London.



Encouragingly, there is evidence to suggest that testing by GPs, genito-urinary medicine (GUM) clinics and A&E has increased since 2010 (Figure 18).


**Figure 18: Number of hepatitis C tests by service type in sentinel laboratories by year in London, 2010–2014.**<sup>6</sup> Please note that the numbers relate to those tested in the sentinel laboratories, and do not represent all tests across London.



## People who inject drugs

There is a long-term, gradual trend for increased testing of PWID. The PHE’s Unlinked Anonymous Monitoring (UAM) Survey of PWID monitors levels of risk and protective behaviours among PWID. It is encouraging to see that the proportion of PWID taking up the offer of a hepatitis C test has increased in the past 10 years to 87% in London in 2014 (Figure 19).<sup>7</sup>


**Figure 19: Hepatitis C test uptake among PWID and their awareness of infection in London, 2005–14.<sup>7</sup>**



However, 41% of PWID remain unaware of their infection. While hepatitis C testing has been shown to be acceptable, this reflects the need for more frequent testing.

Reported testing among clients of drug treatment services in London has also increased. In 2013/14, 80% of eligible clients received a hepatitis C test, a rise from 66% in 2010/11.<sup>19</sup> This was the same as seen in England (80%), but varied considerably by LA in London, with four LAs testing less than 70% of eligible clients (Figure 20).

**Figure 20: Proportion of clients of drug treatment services eligible and received a hepatitis C test by local authority in London 2013/4<sup>19</sup>**



According to a survey of London commissioners and providers in 2012, dried blood spot testing was reported **by commissioners** to be available in 63% (15/24) of drug treatment services, whereas providers only reported it being available in 37% (14/38).<sup>20</sup> The same survey identified that the hepatitis C testing services were commissioned from drug treatment services by a block contract (11/24, 46%) or as one part of a larger block contract (5/24, 21%).<sup>20</sup>

## Testing in prisons

Only a small proportion of prisoners are reported as being tested for hepatitis C in London in 2013 (6.4%), which is a slight increase on 2012/13 (5.7%) but less than the English average (7.9%) (Table 3).<sup>21</sup> Only HMP Pentonville and HMP Isis reported testing more than 10% of new receptions; however it should be noted that reporting is often incomplete.

The audit of hepatitis C services in a sample of English prisons<sup>22</sup> recommended that prisons should ensure that in-house treatment of hepatitis C is available and that laboratories should automatically undertake PCR testing of all positive hepatitis C antibody tests.

**Table 3: Hepatitis C testing in prisons in London, NHS Trust Development Authority, Prison Health Reporting System, 2013<sup>21</sup>**

LA	Prison	Number of receptions	Number of hepatitis C tests performed within 31 days of reception	% of receptions with a hepatitis C test performed within 31 days of reception
Greenwich	Belmarsh (HMP)	3,830	39	1.0%
Lambeth	Brixton (HMP)	1,785	0	0.0%
Hounslow	Feltham (HMYOI/RC)	2,744	0	0.0%
Islington	Holloway (HMP/YOI)	2,006	162	8.1%
Greenwich	Isis (HMP)	922	100	10.8%
Islington	Pentonville (HMP)	6,264	1,663	26.5%
Greenwich	Thameside (HMP)	5,650	13	0.2%
Wandsworth	Wandsworth (HMP)	6,311	208	3.3%
Hammersmith & Fulham	Wormwood Scrubs (HMP)	5,958	82	1.4%
<b>London</b>		<b>35,470</b>	<b>2,267</b>	<b>6.4%</b>
<b>England</b>		<b>210,197</b>	<b>16,512</b>	<b>7.9%</b>

New national indicators, Health and Justice Indicators of Performance (HJIPs), have been developed in England for use by commissioners and partners to monitor the quality and performance of healthcare in all prescribed places of detention. HJIPs will support the introduction of HCV opt-out testing in England including the offer and uptake of HCV testing.

### 3. Prevention and harm reduction

Prevention strategies primarily focus on injecting drug use because this is the most important risk factor for acquisition of the virus in England today.

Reducing the number of individuals who begin injecting drugs; encouraging injectors to quit injecting; reducing risky behaviour (eg sharing needles and syringes) in those who continue to inject; and the early diagnosis and treatment of those who become infected with hepatitis C are all components of the prevention programme.

The delivery of successful prevention programmes in this challenging risk group requires the integrated input of government, professional organisations, and public health and healthcare professionals from a variety of clinical, social and drug service backgrounds.

#### People who inject drugs

There has been a 10-year downward trend in the proportions of PWID that report sharing equipment, with 15% reporting direct sharing and 32% reporting both direct and indirect sharing in 2014 (Figure 21). Direct sharing is the sharing of needles and syringes among those who injected in the previous four weeks. Indirect sharing is the sharing of mixing containers, filters or the water used to prepare drugs.

**Figure 21: Level of direct and indirect sharing among PWID in London, 2005–2014<sup>7</sup>**



In England, indirect measures of needle and syringe programme (NSP) coverage suggest that the vast majority of PWID are accessing NSP; in 2014, the UAM Survey found that 85% of people who had injected drugs in the previous year reported that they had used an NSP during that time<sup>2</sup>. While data suggests that NSP are being accessed by many PWID, there remains a need to increase the amount of equipment distributed in many areas, with better targeting of this provision and education on appropriate needle and syringe cleaning techniques.

## Prisoners

The audit of selected English prisons in 2013 revealed that almost two-thirds of those audited (62%, 13/21 prisons) had written hepatitis C documentation in place.<sup>22</sup> Neither HMP Wormwood nor Brixton, the two London prisons that participated in the audit, had any form of written document. This level of documentation was lower than that published by the survey in July 2012, when the proportion was 74% (82/110).<sup>23</sup> The majority (81%, 17/21) of the prisons reported having disinfectant tablets available, including HMP Brixton, although HMP Wormwood did not. Disinfectant tablets are used to sterilise injecting equipment.



## 4. Treatment of individuals with hepatitis C

Antiviral treatments that will successfully clear the virus in the majority of patients are available and approved for use in the UK.<sup>24-32</sup> Newer treatments have improved effectiveness, reduced treatment durations and fewer side-effects. However, the cost of the new treatments, when coupled with the numbers potentially requiring them, raises real issues of affordability for UK health services.

NHS England is responsible for commissioning and funding access to the newer drugs for hepatitis C and has recently announced national investment to deliver the drugs to those patients with cirrhosis who are in the most need. The new drugs will be delivered via operational delivery networks (ODN) under a 'hub and spoke' model<sup>33</sup>. There will be four 'hub' hospitals in London, with local hospitals acting as 'spokes'. Local 'spoke' hospitals will be able to refer patients into the hub for approval of treatment with the new drugs.

Only a small proportion of those tested for hepatitis C have typically received treatment. This may have been due to issues around referral, for example patients were not appropriately referred to a specialist or did not attend appointments. Some people found it difficult to adhere to long-term treatment. Furthermore, many individuals affected by hepatitis C are from marginalised populations such as PWID or the prison population, who often find it difficult to access treatment in specialist hospital settings.

If the infected population is left untreated, the number of patients with severe hepatitis C related diseases will continue to increase and represent a substantial future burden on healthcare resources.

This can be mitigated by increasing treatment uptake, which will have the greatest impact if implemented quickly.<sup>34</sup> Introduction of new treatment regimens would be expected to improve treatment uptake, compliance and outcomes. Co-ordination of high quality services for assessment and treatment was one of the key issues identified in the *Hepatitis C Action Plan for England*.

Statistical modelling suggests that increased uptake and new therapies are both needed to avert rises in hepatitis C-related ESLD in England. Preliminary results from further modelling suggest that extending new treatments, with their markedly improved rates of sustained virological response, to just 2,000 people in England with cirrhosis per year from 2015 would have a significant impact on the incidence of hepatitis C-related ESLD/HCC, with 5,220 people predicted to consequently be living with hepatitis C-related cirrhosis or HCC in 2020 compared to 11,710 if the new treatments were only given to people with ESLD/HC. However, without increasing new treatments in those


with moderate disease, reductions in numbers of people with hepatitis C-related ESLD/HCC would not continue beyond five years.

Modelling studies have also shown that while strategies prioritising persons with advanced liver fibrosis have the most advantageous impact on severe liver morbidity, they are suboptimal in terms of curtailing incident transmission.

### Estimates of numbers receiving therapy for hepatitis C

Currently, there are no national surveillance systems to monitor referral, uptake or response to treatment. PHE has previously used national data from pharmaceutical companies, pharmacy purchasing data and pharmacy prescribing data to estimate how many individuals have been treated for hepatitis C in England (Figure 22).<sup>35</sup>

**Figure 22: Estimated numbers of hepatitis C positive patients receiving combined therapy based on national supply of pegylated interferon by region, 2006–2011<sup>35</sup>**



In addition to the usual contractual reporting that providers are required to provide to commissioners, work is underway to agree arrangements for the collection of further epidemiological, treatment and outcome data to add to the understanding of hepatitis C in England and the effectiveness of the new treatments. A dataset has been agreed with the involvement of clinicians, patient representatives and PHE; and work is underway to validate that it meets clinical requirements and to confirm how these data will be collected, stored and analysed.

There is a lack of recent information for London. Up until 2011, the trend was for an increase in the numbers of hepatitis C positive patients receiving treatment in London. In 2011, 1,492 individuals were treated (Figure 22). London had much higher numbers

treated than any other PHE Centre, which likely reflects the large population and a higher burden of infection.

Sentinel surveillance data in England suggest that the number of individuals experiencing treatment for the first time increased between 2002 and 2009 but has declined since; when most recent treatment events are examined, the numbers undergoing treatment have increased year on year between 2002 and 2014<sup>2</sup>.

## Care pathways

It is essential that robust treatment care pathways are in place in order for patients to be referred and treated appropriately.

## People who inject drugs

Overall across the UK, data suggests that referrals for hepatitis C treatment and care are rising. Among UAM survey participants in England and Wales with antibodies to hepatitis C who were aware of their infection, increasing numbers of PWID report having seen a specialist nurse or doctor about their infection, with around 70% reporting having done so in the 2013 and 2014 surveys<sup>2, 7</sup>.

Previous evidence suggests that only a minority of areas in London had treatment care pathways for PWID. The London Joint Working Group on Substance Misuse and Hepatitis C (LJWG) undertook a survey of substance misuse commissioners and providers in 2012, with responses from 73% (24/33) of commissioners and 38 providers. Only a third of commissioners (11/38, 29%) and a third of providers (12/38, 32%) reported having a documented patient pathway for PWID with hepatitis C. Over half of the commissioners who responded to the survey (14/24, 58%) were able to provide an account of the mechanism employed to follow up referrals into specialist services. Of the boroughs with a mechanism in place, half included follow up and monitoring as the remit of the blood borne virus specialist nurse, and six relied on the service user's key worker to monitor outcomes of referral. One borough employed assertive outreach to increase attendance in specialist services.

Where information was available (11 providers), providers reported that a quarter (26%) of clients with chronic hepatitis C infection had initiated treatment in the preceding 12 months. Two providers reported that hepatitis C treatment was offered as an integrated part of the drug treatment service. The other nine providers reported that 28% of all referrals resulted in clients initiating treatment.

## Prisons

It is important that prisons have a clear and accessible pathway in place for hepatitis C testing, treatment and care. The pathway should be designed to meet the challenges of both the prison environment and continuity of care in the community. As a matter of good practice, prisons should offer proactive and targeted diagnostic testing for hepatitis C. Laboratories should ensure that all blood samples that test positive for hepatitis C antibody (a marker of whether someone has ever been infected) should be routinely tested by PCR as the first step in accessing a care pathway in prison. The PCR test is needed to identify those who remain infected, as opposed to those who have cleared the infection.

The results of a survey published in July 2012 indicate that only 25% (2/8) of prisons in London had a written pathway in place to describe what happens following a positive result (HMP Holloway and HMP Brixton).<sup>23</sup> All the prisons that responded indicated that they use venous blood, as opposed to dried blood spot, to test for hepatitis C and just half indicated that their laboratory automatically tests using PCR.

The majority of London prisons (6/8) referred to hospital outpatients for treatment, with the others using an 'in reach' service provided by the hospital (HMP Belmarsh and HMP Wandsworth). HMP Belmarsh conducted appointments via video link, which cuts down on costs such as escorts and health specialist time. All the prisons indicated that they provided referral for those leaving prison who are hepatitis C positive if these prisoners were released into the community.

The 2013 prison audit, in which 21 prisons participated, covered key areas of best practice including health promotion, testing, treatment and care for hepatitis C in prison.<sup>22</sup> Recommendations from the audit included:

- prisons should ensure in-house treatment of hepatitis C is available
- laboratories should automatically undertake PCR testing of all positive hepatitis C antibody tests

## Acknowledgements

The authors would like to thank the following:

### Public Health England, Centre for Infectious Disease Surveillance and Control

- Lukasz Cieply & Koye Balogun, PHE (Laboratory reports)
- Lukasz Cieply & Sam Lattimore, PHE (Sentinel Surveillance of Blood-borne Virus Testing & oral fluid testing data provided by Concateno Plc)
- Vivian Hope and Katelyn Cullen, PHE (Data from Unlinked Anonymous Monitoring Survey of HIV and Hepatitis in PWID)
- Annastella Costella, Helen Harris, Ross Harris, Vivian Hope, Sema Mandal, Mary Ramsay (Commissioning Template for Estimating Hepatitis C Prevalence by PCT and Numbers Eligible for Treatment)
- Sam Lattimore (The Enhanced Surveillance of Newly Acquired Hepatitis C infection in men who have sex with men)
- Annastella Costella, Philip Keel (Admissions, Deaths, Transplants)

### Public Health England, Health and Wellbeing

- Kevin Shelton, Jonathan Alderson (Drug services hepatitis C testing data)

### Public Health England London

- Rebecca Cordery, Gee Yen Shin, Deborah Turbitt for comments

### Public Health England Field Epidemiology Services (FES)

- Rehman Teagle, Sophie Newitt, Obaghe Edeghere (compilation of the regional template report & collated each PHE Centre's data) FES, West Midlands
- Piers Mook, FES South East and London

### NHS Trust Development Authority

- John Hastings (Prison hepatitis C testing data)

## The Office for National Statistics

- The Office for National Statistics (ONS carried out the original collection and collation of the data but bear no responsibility for their future analysis or interpretation) for providing data used in this report

## The Health and Social Care Information Centre (HSCIC)

- HSCIC for providing the Hospital Episode Statistics data used in this report; (Copyright © 2015, re-used with the permission of The Health and Social Care Information Centre, all rights reserved)

# Data sources

## Sentinel Surveillance of Hepatitis Testing Study

This was set up in 2002 to enhance routine surveillance of hepatitis C. The study collects data on laboratory test results and demographic data for all individuals tested for hepatitis C antibody in 24 sentinel laboratories in England, covering approximately one third of the population.

There are eight participating centres in London—PHE CIDSC, North Middlesex Hospital, St Bartholomew's Hospital, King's College Hospital, Ealing Hospital, St George's Hospital, Chelsea and Westminster Hospital, Dulwich Laboratory and University College Hospital.

Limitations of the data include: some duplication of individual patients; exclusion of dried blood spot, oral fluid, reference testing; and exclusion of testing from hospitals referring all samples that do not have the original location identified. Individuals aged less than one year are excluded because positive tests in this group may reflect the presence of passively-acquired maternal antibody rather than true infection.

## Unlinked Anonymised Monitoring Survey of People Who Inject Drugs

This survey measures the changing prevalence of hepatitis C in current and former PWID who are in contact with 60 specialist drug agencies (eg needle exchange services and treatment centres) in England, Wales and Northern Ireland. The programme also monitors levels of risk and protective behaviours among PWID.

## About Field Epidemiology Services

The Field Epidemiology Service (FES) supports Public Health England Centres and partner organisations through the application of epidemiological methods to inform public health action.

FES does this in two main ways, firstly by providing a flexible expert resource, available, as and when needed, to undertake epidemiological investigations for key health protection work and secondly through the expert analysis, interpretation and dissemination of surveillance information to PHE Centres, local health partners, service providers and commissioners of services.

Within the FES network, excellence and innovation is encouraged, we foster academic collaborations and take active part and lead in research, development and training.

You can contact your local FES team at [fes.seal@phe.gov.uk](mailto:fes.seal@phe.gov.uk)

If you have any comments or feedback regarding this report or the FES service, please contact [fes.seal@phe.gov.uk](mailto:fes.seal@phe.gov.uk)

## Appendix 1

Local authority data on laboratory reports of hepatitis C is presented in Table A1. Due to incomplete reporting extreme caution should be applied when using this data as it is unlikely to robustly represent the true rate of laboratory reports in each local authority.

Where possible, data is summarised by upper tier local authority of residence. However, where data on patient postcode or registered GP practice is not available, data is assigned to the local authority of the laboratory.

In 22% of reports, the data was assigned to the local authority of the laboratory. This means that there will be a bias to observing increased reports in those local authorities where laboratories are located.



**Table A1: Laboratory reports of hepatitis C by local authority in London, 2014<sup>5</sup>**

Local authority	No. of laboratory reports	Directly standardised rate (DSR) per 100,000 population*		
		DSR	95% lower confidence interval	95% upper confidence interval
Barking and Dagenham	42	23.3	16.3	32.2
Barnet	114	33.3	27.4	40.2
Bexley	17	7.5	4.3	12.0
Brent	130	47.3	39.1	56.6
Bromley	35	11.3	7.9	15.7
Camden	332	152.1	135.1	170.6
City of London	10	106.0	43.5	209.4
Croydon	145	39.7	33.4	47.0
Ealing	169	51.8	43.9	60.7
Enfield	113	33.5	27.1	40.9
Greenwich	109	40.8	33.1	49.8
Hackney	150	69.7	57.5	83.6
Hammersmith and Fulham	146	105.8	88.2	125.7
Haringey	103	35.7	27.9	44.9
Harrow	40	16.4	11.7	22.5
Havering	44	17.6	12.6	23.9
Hillingdon	77	27.9	21.8	35.1
Hounslow	97	37.1	29.8	45.6
Islington	134	74.8	61.8	89.6
Kensington and Chelsea	250	159.4	139.5	181.2
Kingston upon Thames	43	25.7	18.4	34.8
Lambeth	362	110.2	97.9	123.5
Lewisham	87	30.9	24.2	38.8
Merton	32	16.1	10.7	23.1
Newham	183	66.8	56.2	78.6
Redbridge	80	27.7	21.7	34.9
Richmond upon Thames	18	9.3	5.5	14.8
Southwark	142	49.2	40.9	58.6
Sutton	54	27.0	20.2	35.4
Tower Hamlets	231	89.4	76.0	104.3
Waltham Forest	85	30.5	24.0	38.0
Wandsworth	98	34.4	27.2	42.8
Westminster	186	89.3	76.2	103.9
<b>Total</b>	<b>3,858</b>	<b>47.0</b>	<b>45.5</b>	<b>48.6</b>

\*DSRs per 100,000 population have been calculated using mid-year population estimates supplied by the Office for National Statistics

## Appendix 2

**Table A2: Estimates of hepatitis C prevalence, burden, and treatment by DAT in London <sup>10</sup> (please see notes on the next page for interpretation and the notes on the original models available on the PHE website <http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/HepatitisC/EpidemiologicalData/>)**

DAT	Estimated total infected population	Estimated Burden in 2023				Estimated no. of backlog of current diagnosed infections requiring treatment	Estimated additional number of annual new diagnoses requiring treatment
		Mild/moderate	Cirrhotic/ESLD/HCC	Died	SVR*		
Barking and Dagenham	1,221	573	51	139	79	108	22
Barnet	1,686	791	71	192	109	149	30
Bexley	1,178	553	50	134	76	104	21
Brent	2,089	980	88	238	136	184	37
Bromley	1,356	636	57	154	88	120	24
Camden	3,002	1408	126	342	195	265	53
City of London	69	33	3	8	4	6	1
Croydon	2,049	962	86	233	133	181	36
Ealing	2,183	1024	92	249	142	193	39
Enfield	1,620	760	68	184	105	143	29
Greenwich	2,111	991	89	240	137	186	37
Hackney	2,100	985	88	239	136	185	37
Hammersmith & Fulham	1,441	676	61	164	93	127	26
Haringey	1,729	811	73	197	112	153	31
Harrow	1,260	591	53	143	82	111	22
Havering	1,133	531	48	129	73	100	20
Hillingdon	1,609	755	68	183	104	142	29
Hounslow	1,728	811	73	197	112	153	31
Islington	2,231	1047	94	254	145	197	40

DAT	Estimated total infected population	Estimated Burden in 2023				Estimated no. of backlog of current diagnosed infections requiring treatment	Estimated additional number of annual new diagnoses requiring treatment
		Mild/moderate	Cirrhotic/ESLD/HCC	Died	SVR*		
Kensington and Chelsea	1,137	534	48	129	74	100	20
Kingston upon Thames	865	406	36	98	56	76	15
Lambeth	3,605	1691	152	410	234	318	64
Lewisham	2,229	1046	94	254	145	197	40
Merton	1,125	528	47	128	73	99	20
Newham	2,785	1307	117	317	181	246	49
Redbridge	1,815	851	76	207	118	160	32
Richmond upon Thames	866	406	36	99	56	76	15
Southwark	2,921	1371	123	333	189	258	52
Sutton	1,110	521	47	126	72	98	20
Tower Hamlets	2,839	1332	119	323	184	251	50
Waltham Forest	1,791	840	75	204	116	158	32
Wandsworth	2,179	1023	92	248	141	192	39
Westminster	3,100	1454	130	353	201	274	55
<b>London</b>	<b>60,162</b>	<b>28,228</b>	<b>2,531</b>	<b>6,848</b>	<b>3,901</b>	<b>5,310</b>	<b>1,068</b>

\*SVR=sustained virological response  
Please see notes overleaf

This template has been produced to help local authorities (LA) and health and wellbeing boards estimate the prevalence of hepatitis C virus (HCV) infection in their local population, and the likely disease burden. Estimates are produced for drug action team (DAT) areas, which in many cases are equivalent to LAs. The template draws heavily on methods produced for estimating HCV prevalence at a national level, with limited data available at a local level. The estimates produced by this template are therefore naturally less accurate than national estimates, as assumptions must be made about the distribution of HCV prevalence at the local level that do not fully reflect local variation and differences in populations. These assumptions must be borne in mind when interpreting the output from this template. Similarly, projections of current and future morbidity, and rates of diagnosis and treatment are based on national or regional estimates.

This template is an update of the 2011 template. Where possible, data sources have been updated based on recent modelling work, and some improvements to the methodology have been made. In a minority of cases, this has resulted in substantial changes in estimates of local prevalence. Again, it must be stressed that any observed differences should not necessarily be interpreted as genuine changes in prevalence over time, and are at least in part due to changes in the data and methods used. For example, estimates at drug action team (DAT) level for the prevalence of opiate and crack-cocaine injecting, published by the National Treatment Agency (NTA, now part of Public Health England) have changed substantially over time, local HCV prevalence estimates have shifted due to some previously sampled DATs no longer being sampled (and vice versa), and the methodology for estimating the prevalence of ex-injectors has been refined. In some cases, these factors work in conjunction, resulting in a significant difference compared to previous estimates.

Crucially, the local level estimates do not account for the statistical uncertainty of the estimates, ie it is not possible to produce confidence intervals that would give an indication of upper and lower bounds for these estimates. Future modelling work will aim to incorporate data at a more local level, and estimate local prevalence within a formal statistical model, which will allow this uncertainty to be reported.

## References

1. Harris RJ, Ramsay M, Hope VD, Brant L, Hickman M, Foster GR, et al. Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. *The European Journal of Public Health*. 2012;22(2):187-92.
2. Public Health England. Hepatitis C in the UK: 2015 Report. 2015. Available from: [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/448710/NEW\\_FINAL\\_HCV\\_2015\\_IN\\_THE\\_UK\\_REPORT\\_28072015\\_v2.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/448710/NEW_FINAL_HCV_2015_IN_THE_UK_REPORT_28072015_v2.pdf).
3. World Health Organisation. EASL International Consensus Conference on Hepatitis C. Consensus statement. 1999.
4. Health Protection Agency. Laboratory Reporting to the Health Protection Agency, Guide for Diagnostic Laboratories. 2010.
5. Public Health England. Laboratory Surveillance Data.
6. Public Health England. Sentinel Surveillance of Blood-borne Virus Testing.
7. Public Health England. Unlinked Anonymous Survey of People Who Inject Drugs.
8. National Institute for Health and Clinical Excellence. Hepatitis B and C: ways to promote and offer testing to people at increased risk of infection. NICE public health guidance 43. 2012.
9. Public Health England. The Enhanced Surveillance of Newly Acquired Hepatitis C infection in men who have sex with men (SNAHC).
10. Public Health England. PHE Commissioning Template for Estimating HCV Prevalence by PCT and Numbers Eligible for Treatment. 2014.
11. Public Health England. Shooting Up: Infections among people who inject drugs in the UK 2012. An update: November 2013. 2013. Available from: <http://www.hpa.org.uk/Publications/InfectiousDiseases/BloodBorneInfections/ShootingUp/1311ShootingupInfectionsamongIDUS/>.
12. Health and Social Care Information Centre. Hospital Episode Statistics (HES).
13. Public Health England. Liver Disease Profiles. 2015 [25 September 2015]; Available from: <http://fingertips.phe.org.uk/profile/liver-disease>.
14. NHS Blood and Transplant. 2013.

15. Office of National Statistics. Death certification.
16. Department of Health. Hepatitis C Action Plan for England 2004. 2004. Available from: [http://www.dh.gov.uk/prod\\_consum\\_dh/groups/dh\\_digitalassets/@dh/@en/documents/digitalasset/dh\\_4084713.pdf](http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4084713.pdf).
17. Department of Health. Hepatitis C. Get Tested. Get Treated. 2007. Available from: <http://www.nhs.uk/hepatitisc/Pages/default.aspx>.
18. Department of Health. Hepatitis C. The more you know, the better.
19. National Drug Evidence Centre University of Manchester on behalf of Public Health England. National Drug Treatment Monitoring System.
20. London Joint Working Group on Substance Misuse and Hepatitis C. Public Health Report on Commissioning of HCV services in London for People who Inject Drugs. 2013.
21. NHS Quality Observatory. Prison Health Performance & Quality Indicators (PHPQIs).
22. Public Health England and Department of Health. An audit of hepatitis C services in a representative sample of English prisons. 2013. Available from: [http://www.hpa.org.uk/webc/HPAwebFile/HPAweb\\_C/1317139084753](http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139084753).
23. Department of Health. National Survey of hepatitis C services in prisons in England. 2012.
24. NHS England. Interim Clinical Commissioning Policy Statement: Sofosbuvir + Daclatasvir/Ledipasvir +/- Ribavirin for defined patients with Hepatitis C. 2014. Available from: <http://www.england.nhs.uk/wp-content/uploads/2014/04/sofosbuvir-pol-stat.pdf>.
25. National Institute for Health and Clinical Excellence. Sofosbuvir for treating chronic hepatitis C. NICE technology appraisal guidance TA330. 2015.
26. National Institute for Health and Clinical Excellence. Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C. NICE technology appraisal guidance TA331. 2015. Available from: <http://www.nice.org.uk/guidance/ta331>.
27. National Institute for Health and Clinical Excellence. TA75 Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. 2004. Available from: <http://www.nice.org.uk/nicemedia/pdf/TA075guidance.pdf>.
28. National Institute for Health and Clinical Excellence. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. 2006. Available from: <http://www.nice.org.uk/nicemedia/live/11590/33534/33534.pdf>.

29. National Institute for Health and Clinical Excellence. TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. Part review of NICE technology appraisal guidance 75 and 106. 2010. Available from: <http://www.nice.org.uk/nicemedia/live/13180/50856/50856.pdf>.
30. National Institute for Health and Clinical Excellence. Telaprevir for the treatment of genotype 1 chronic hepatitis C. 2012. Available from: <http://guidance.nice.org.uk/TA252>.
31. National Institute for Health and Clinical Excellence. Boceprevir for the treatment of genotype 1 chronic hepatitis C. 2012. Available from: <http://guidance.nice.org.uk/TA253>.
32. National Institute for Health and Clinical Excellence. Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people. NICE technology appraisal guidance TA300. 2013. Available from: <http://www.nice.org.uk/guidance/ta300>.
33. NHS England. Treatment of chronic hepatitis C in patients with cirrhosis Interim Clinical Commissioning Policy Statement. NHS England Clinical Reference Group for Infectious Diseases. 2015. Available from: [www.england.nhs.uk/commissioning/wpcontent/uploads/sites/12/2015/06/hep-c-cirrhosis-policy-statement-0615.pdf](http://www.england.nhs.uk/commissioning/wpcontent/uploads/sites/12/2015/06/hep-c-cirrhosis-policy-statement-0615.pdf).
34. Harris R, Thomas B, Griffiths J, Costella A, Chapman R, Ramsay M, et al. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: Modelling the predicted impact of treatment under different scenarios. *Journal of Hepatology*. 2014;61:530-7.
35. Roche Sales IMS Supply Chain Manager data Pharmex. Estimated numbers of HCV positive patients receiving combined therapy based on national supply of pegylated interferon by region. 2006-2011.